ArticleRedox biology2026
Serum malondialdehyde predicts mortality in patients with acute heart failure.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Oxidative Stress to Fibrotic Remodeling: Integrating Redox Biology, Galectin-3, and Imaging Phenotypes in Heart Failure.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAcute heart failure (AHF) is associated with high short- and long-term mortality, and early identification of patients at highest risk remains challenging despite the use of established biomarkers and clinical risk scores. Oxidative stress plays a central role in the pathophysiology of AHF but has been insufficiently investigated as a prognostic target. This study aimed to evaluate the prognostic value of serum oxidative stress biomarkers for predicting short- and long-term mortality in AHF patients and to determine whether they improve risk stratification beyond established tools.
methodsAdmission serum levels of malondialdehyde (MDA), advanced oxidation protein products (AOPPs), catalase, and superoxide dismutase (SOD) were measured in a cohort of 315 hospitalized AHF patients. Univariable and multivariable logistic regression analyses were performed to assess associations with in-hospital, 6-month, and 12-month mortality. Prognostic performance was compared with N-terminal pro-brain natriuretic peptide (NT-proBNP) and established risk scores (ADHERE, GWTG-HF, OPTIMIZE-HF) using receiver operating characteristics curves, the continuous net reclassification index (cNRI) and decision curve analysis.
resultsSerum MDA, catalase, and SOD were significantly elevated in non-survivors at all time points. In the adjusted analyses, MDA was the only oxidative stress marker independently associated with mortality. MDA showed robust prognostic performance, with improvements in AUC and cNRI as well as increased net benefit, when added to NT-proBNP or clinical scores. Survival analysis confirmed lower survival in patients with MDA ≥1.45 nmol/L (the median in our cohort). Other biomarkers (AOPPs, catalase, SOD) showed limited prognostic utility.
conclusionSerum MDA is a robust, independent predictor of mortality in AHF. Incorporating MDA into routine assessment may enhance early identification of high-risk patients and support personalized management strategies in AHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.